Back when Brandy Matthews, M.D., was seeing Alzheimer’s disease patients as a behavioral neurologist, she found the most important thing she could offer was information.
The FDA still hasn’t found what its looking for in TG Therapeutics’ application for the leukemia and lymphoma combo treatment nicknamed U2, and so the therapy will be examined at an advisory committee meeting.
Mei Pharma’s bid to break into a congested market fought over by Bayer and Gilead has yielded data. The pivotal trial linked zandelisib to a 70% response rate in follicular lymphoma patients but leaves scope to question whether the drug is differentiated enough to crack a competitive space.
After toiling for 40 years, ImmunoGen can now see the potential approval of its first wholly owned oncology drug on the horizon. The biotech is preparing to submit mirvetuximab soravtansine for approval after showing the antibody-drug conjugate (ADC) shrank ovarian tumors.
Philips raised the curtain on a new portfolio of smart MRI machines equipped with artificial intelligence programs to help speed up image acquisition and diagnosis as well as a new scanner combining spectral CT with real-time, image-guided therapy hardware.
As it nears the halfway point of its BD2025 plan to accelerate companywide growth and stakeholder value, BD has tapped a seasoned exec from one of its competitors to oversee all investor-facing communications.
Nearly three months into her federal trial over a dozen counts of fraud, Elizabeth Holmes took the stand last week, undergoing questioning by her defense team that has so far stretched across three days.
Immune cells are integral to tamping down inflammatory responses, and one such cell central to autoimmune diseases is the dendritic cell. Now, researchers in Japan have found a molecule important to the activity of the receptor that regulates dendritic cells and is likely involved in the development of arthritis and other autoimmune diseases.
Medtronic’s early international rollout of its Hugo surgical robot is going slower than expected, thanks to crimps in the global supply chain and initial manufacturing issues, according to the medtech giant’s chairman and CEO, Geoff Martha.
Acorda Therapeutics is losing another employee. After seeing colleagues depart in waves of layoffs in recent years, Acorda Chief Medical Officer Burkhard Blank, M.D., is leaving to take up a position at Pharnext.